Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$124.43
neg -0.43
-0.34%
Today's Range: 123.76 - 125.45 | CELG Avg Daily Volume: 4,260,800
Last Update: 03/28/17 - 4:00 PM EDT
Volume: 3,059,647
YTD Performance: 7.50%
Open: $124.61
Previous Close: $124.86
52 Week Range: $92.98 - $137.54
Oustanding Shares: 777,966,471
Market Cap: 97,136,893,569
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 15 15 15 15
Moderate Buy 0 0 0 0
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.24 1.24 1.24 1.24
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 50.14
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
50.14 50.10 30.30
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.09% 25.41% 78.66%
GROWTH 12 Mo 3 Yr CAGR
Revenue 21.30 0.70 0.20
Net Income 24.80 0.40 0.11
EPS 28.40 0.50 0.14
Earnings for CELG:
EBITDA 3.71B
Revenue 11.23B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $1.47 $1.60 $6.60 $8.16
Number of Analysts 8 4 4 3
High Estimate $1.55 $1.67 $6.83 $8.50
Low Estimate $1.41 $1.54 $6.51 $7.80
Prior Year $1.18 $1.28 $5.18 $6.60
Growth Rate (Year over Year) 24.58% 24.61% 27.46% 23.59%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Doug Kass

 | Mar 27, 2017 | 5:15 PM EDT
For the first time in six years the DJIA fell for the eighth consecutive day. That said the Nasdaq has risen in ten of the last thirteen trading sessions as Donald Trump may be making volatility and uncertainty great again. (For that divergence and other reasons, in "Its All Relative" I like the long [SPDR S&P 500 ETF Trust] (SPY) /short [PowerShares QQQ Trust, Series 1 (ETF)] (QQQ) pairs trade). 
RMPIA
By

Doug Kass

 | Mar 21, 2017 | 5:47 PM EDT
Risk happens fast. 
RMPIA
By

Robert Lang

 | Mar 17, 2017 | 10:00 AM EDT
Strong biotech stock has surged since November and is close to all-time highs.
RMPIA
By

Jim Cramer

 | Mar 15, 2017 | 1:34 PM EDT
This reversal has been incredible to watch.
RMPIA
By

Doug Kass

 | Mar 13, 2017 | 12:47 PM EDT
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (XLV) (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. Last year more than $18 billion was redeemed out of the healthcare ETFs, according to Morningstar. However there are some technical signposts that the two-year period of underperformance might be ending, as a basing seems likely. Look at the chart and note the recent higher high.
RMPIA
By

Doug Kass

 | Mar 9, 2017 | 3:57 PM EST
This is a great invite, "Wall Street Goes to Washington," in which legendary journalist Michael Wolff will sit down with my pal, The Mooch! And it's free! 
RMPIA
By

Doug Kass

 | Mar 8, 2017 | 3:59 PM EST
 
RMPIA
By

Jim Cramer

 | Feb 27, 2017 | 12:27 PM EST
There are nearly too many surging sectors to count.
RMPIA
By

Bret Jensen

 | Feb 22, 2017 | 10:00 AM EST
These two large-cap drug giants should be core parts of any well-diversified portfolio.
RMPIA
By

Doug Kass

 | Feb 21, 2017 | 2:55 PM EST
 

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.